Bayer: Prostate Cancer Drug Xofigo Approved in China
August 27 2020 - 3:18AM
Dow Jones News
By Cecilia Butini
Bayer AG said Thursday that its prostate cancer drug Xofigo, or
radium-223 dichloride, was approved by the Chinese Medical Products
Administration.
The drug, which is defined as a Targeted Alpha Therapy, is
indicated in the treatment of patients with castration-resistant
prostate cancer who also have symptomatic bone metasthases and no
known visceral metasthases, the German pharmaceutical and chemical
conglomerate said.
Xofigo is already approved in more than 50 countries, including
the U.S., the European Union and Japan, Bayer said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
August 27, 2020 04:03 ET (08:03 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
From Apr 2024 to May 2024
Bayer (TG:BAYN)
Historical Stock Chart
From May 2023 to May 2024